Drug experts to review safety concerns for 3 asthma drugs

A panel of drug experts will review three asthma therapies today to determine if they should stay on the market after a small number of cases were reported by patients who said the drugs were associated with severe asthma exacerbations. The drugs are GlaxoSmithKline's Advair and Serevent and Novartis' Foradil. Two of the drugs contain the active ingredient salmeterol. Foradil contains formoterol. Advair and Serevent both feature warnings of a small increase in the number of deaths of patients who added the drug to their asthma therapies. A number of drug experts are expected to testify on behalf of the drugs' efficacy in treating asthma.

- read this story from The New York Times for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.